Navigation Links
Neurotrope Bioscience to Present at the Noble Financial Capital Markets' 13th Annual Investor Conference
Date:1/27/2017

NEW YORK, Jan. 27, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, is scheduled to present at the Noble Financial Capital Markets' 13th Annual NobleCON Conference, being held January 29-31, 2017 at the Boca Raton Resort in Boca Raton, Florida.

Details of the presentation are as follows:

Conference:Noble Financial Capital Markets NobleCON 13Date:Monday, January 30, 2017Time:1:30 p.m. ETLocation:Room 1

A video and audio webcast of Neurotrope's presentation will be available at http://noble.mediasite.com/mediasite/Play/c54248f852db4353b8f007b16745782b1d and on the Company's web site at www.neurotropebioscience.com. The webcast and presentation will be archived on Neurotrope's website following the event.

Investors attending the conferences who would like to schedule a 1-on-1 meeting with Dr. Wilke may do so by contacting their Noble representative, or Jeffrey Benison of Neurotrope.

About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.

The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by bryostatin, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.

Neurotrope is conducting a Phase 2 trial of bryostatin in the treatment of moderate to severe Alzheimer's disease, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin for Alzheimer's disease and other cognitive diseases, and the Company's ability to list its common shares on a major stock exchange. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, the Company's inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition,  stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2015 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. The Company does not undertake to update these forward-looking statements.

Please visit www.neurotropebioscience.com for further information.

For additional information, please contact:
Neurotrope Bioscience, Inc.
Jeffrey Benison, Director of Corporate Communications
212.334.8709 or 516.286.6099
jbenison@neurotropebioscience.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotrope-bioscience-to-present-at-the-noble-financial-capital-markets-13th-annual-investor-conference-300397915.html


'/>"/>
SOURCE Neurotrope, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
2. Neurotrope, Inc., Announces New Trading Symbol
3. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
4. Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs
5. Neurotrope To Host Conference Call
6. Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimers Disease
7. Neurotrope, Inc. Announces $15.3 million Private Placement
8. Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
9. Neurotrope Announces Private Placement of $20 Million
10. Neurotrope Issues Statement On Eli Lillys Solanezumab
11. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... Kathy Goin is joining myClin ... years of expertise in establishing and leading clinical operations at Sponsors including Trevena, ... therapist, through a variety of leadership roles in Clinical Operations, to her current ...
(Date:5/22/2017)... ... ... Stratevi, a boutique firm that partners with healthcare companies to creatively develop ... in downtown Boston at 745 Atlantic Ave. , “We are seeing that even ... the value they provide, not just to patients, but also payers. Having a presence ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is ... trial and error process by finding the right antidepressant faster. CNSDose speeds ... doctor-patient relationship through a personalized approach to treatment. , A peer-reviewed ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u ... Cooking Challenge is a two-hour team-building package designed for groups of 10-30 people. ... Jodi Abel, which include items, such as Blackened Shrimp with Edamame Salad, Pizza ...
Breaking Biology Technology:
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. ... Used combined in one project, multi-biometric solutions ... ...
Breaking Biology News(10 mins):